This was the best quarter in Lilly’s history by virtually every metric. Revenue of $19.8 billion, up 56% year-over-year, smashed the Street consensus of $17.6 billion to $17.8 billion by more than $2 billion. Non-GAAP EPS came in at $8.55 versus consensus of $6.66 to $6.79—a beat of 26% to 28%. Mounjaro alone generated $8.7 billion (+125%), beating estimates by more than $1 billion. Zepbound hit $4.1 billion (+79%). Together, the two GLP-1 injectables produced $12.8 billion in global revenue, meaning GLP-1s now represent roughly two-thirds of Lilly’s total sales. Volume grew 65%, more than offsetting a 13% decline in realized prices driven by the self-pay price cuts Lilly announced last year. Lilly raised full-year revenue guidance by $2 billion to $82 billion to $85 billion and boosted non-GAAP EPS guidance to $35.50 to $37.00. LLY surged approximately 10% on Thursday to close near $935. But the Foundayo narrative is more complicated. CEO David Ricks said more than 20,000 people have started the drug since launch. IQVIA data show 3,707 prescriptions in the week ending April 17—up from 1,390 in the first partial week but well below analyst expectations of approximately 8,000.
Top Story: Lilly Posts Its Best Quarter Ever
What Happened: Eli Lilly reported Q1 2026 financial results on April 30 that exceeded expectations across every major line item.
The Revenue Beat: $2B Above Consensus
Total revenue was $19.8 billion, representing 56% year-over-year growth. The Street had expected $17.6 billion to $17.8 billion. The $2 billion-plus beat was driven almost entirely by the GLP-1 franchise, where demand exceeded even the most optimistic projections.
Non-GAAP EPS was $8.55 versus consensus of $6.66 to $6.79. GAAP EPS was $8.26, up 170% from $3.06 in Q1 2025. GAAP net income was $7.4 billion, up from $2.8 billion a year ago.
U.S. revenue was $12.1 billion, up 43%, driven by a 49% volume increase. Global volume grew 65%, partially offset by 13% lower realized prices—the direct result of the self-pay price reductions Lilly implemented to expand the addressable market.
The GLP-1 Franchise: $12.8B in a Single Quarter
The combined performance of Mounjaro and Zepbound was the story of the quarter:
Mounjaro: $8.7 billion, up 125%. Beat estimates by more than $1 billion. Driven by strong demand globally across both type 2 diabetes and the broader metabolic market.
Zepbound: $4.1 billion, up 79%. Driven by demand growth, partially offset by lower U.S. realized prices from the self-pay price cuts announced last year.
Combined: $12.8 billion from the two injectable GLP-1 products. That represents approximately two-thirds of Lilly’s total quarterly revenue.
The Volume-Versus-Price Dynamic
The most important underlying trend in the quarter is the relationship between volume and price. Lilly cut self-pay prices aggressively last year to expand the addressable market. Those price cuts produced a 13% decline in realized prices. But volume grew 65%, meaning every dollar of price concession was more than compensated by demand expansion.
This is the core of Lilly’s commercial thesis: lower prices create access for more patients, the expanded patient base generates volume growth that exceeds the price decline, and total revenue increases despite lower per-patient revenue. As long as this dynamic holds, Lilly can continue cutting prices—to undercut Novo, to secure government coverage deals, to expand the GLP-1 market from 20 million patients to 30 million and beyond—without sacrificing revenue growth.
CEO Ricks estimated global GLP-1 use will rise from approximately 20 million patients at year-end 2025 to 30 million by year-end 2026. If that 50% growth in the patient base materializes, the volume-over-price dynamic has substantial runway.
Citi analysts wrote that “volume growth of its incretins franchise despite entry of Novo’s Wegovy pill was the biggest question on the Street and proof of continued momentum checks investor score cards.”
Beyond GLP-1: The Diversification Is Working
Key Products revenue in immunology, oncology, and neuroscience grew 160%—the less-noticed but strategically important number in the quarter. Verzenio, Jaypirca, Kisunla, Omvow, and other non-metabolic brands collectively delivered growth that validates the diversification thesis Lilly has been executing through its M&A campaign.
This matters because Lilly’s valuation has been criticized as overly dependent on GLP-1 outcomes. The 160% growth in non-metabolic key products demonstrates that the six acquisitions announced this year—spanning in vivo CAR-T, narcolepsy, ADCs, blood cancer, and AI gene editing—are building on a foundation that is already producing results, not compensating for a single-franchise weakness.
Guidance Raised by $2B
Lilly raised its full-year 2026 guidance:
Revenue: $82 billion to $85 billion (raised from $80 billion to $83 billion). Consensus was $82.1 billion. The raised midpoint ($83.5 billion) sits above consensus.
Non-GAAP EPS: $35.50 to $37.00 (raised from $33.50 to $35.00). Consensus was $34.55. The raised low end exceeds the prior consensus.
An Investment Community Meeting is planned for December 7, 2026, where Lilly will likely lay out its long-term strategy spanning GLP-1s, in vivo CAR-T, oncology, and gene editing. The meeting will be the first opportunity for management to present a unified strategic narrative that integrates the six acquisitions announced this year into a cohesive growth framework. For institutional investors, December 7 will be the event that determines whether Lilly’s M&A campaign is viewed as disciplined portfolio construction or overextension.
The Stock Reaction
LLY surged approximately 10% on Thursday to close near $935, the stock’s biggest single-day gain in months. The magnitude of the move reflects the degree to which the beat exceeded expectations—a $2 billion revenue surprise and a $2 EPS surprise in a single quarter does not happen often at Lilly’s scale. The reaction also suggests that investor concerns about GLP-1 market saturation, pricing pressure, and competitive threats were overweighted heading into the print.
Foundayo Launch: Strong Patient Start, Below-Expectation Prescription Data
What Happened: Foundayo was approved April 1 and launched in Q2, so no revenue was included in Q1 results. CEO Ricks told CNBC that more than 20,000 people have started taking Foundayo since launch. However, IQVIA data show 3,707 U.S. prescriptions in the week ending April 17, below analyst expectations closer to 8,000.
The Numbers in Context
Week 1 (ending April 10): 1,390 prescriptions (approximately two days of capture). Week 2 (ending April 17): 3,707 prescriptions (full week).
That is a 167% increase week over week. The trajectory is pointing up, even though the absolute level is below expectations.
For comparison, Novo Nordisk’s oral Wegovy recorded 18,410 prescriptions in its second full week after launching in January. The gap between Foundayo’s 3,707 and oral Wegovy’s 18,410 at the same stage is significant. Foundayo’s ramp is shallower.
Why the Gap Exists
Several factors may explain the difference. Novo had three months of pre-launch awareness building before oral Wegovy’s first prescriptions were counted. Oral Wegovy was an established brand extending into a new formulation—physicians and patients already knew semaglutide. Foundayo is a completely new brand, new molecule, and new modality. Physician and patient awareness takes time to build for a drug that did not exist in the market six months ago.
Lilly noted that 12-plus major telehealth firms are now offering Foundayo, accounting for about 35% of launch volume. The company also said more than 20,000 patients have started the drug, suggesting some prescriptions are being captured through channels that IQVIA may not fully track—including LillyDirect and certain telehealth platforms that do not report through traditional pharmacy data systems.
What the Analysts Are Saying
RBC’s Trung Huynh said Weeks 8 through 12 are the “earliest window to assess Foundayo’s true commercial momentum.” Analysts have revised 2026 Foundayo revenue estimates from the $4 billion to $5 billion range down to approximately $1.3 billion to $1.7 billion. That lower range is achievable if the weekly prescription trajectory accelerates as retail pharmacy access broadens and telehealth partnerships scale, but it requires a meaningful ramp from current levels.
The Diabetes Filing Adds a Second Growth Vector
Chief Scientific Officer Daniel Skovronsky confirmed the U.S. type 2 diabetes submission for Foundayo will be completed in late Q2 2026, with regulatory action anticipated before year-end. Skovronsky noted that ACHIEVE-4 results showed a 16% lower risk of MACE-4 events and a 23% lower risk of MACE-3 events versus insulin glargine, in addition to the previously reported 57% lower risk of all-cause death.
A diabetes approval would expand Foundayo’s addressable market from roughly 40 million U.S. adults with obesity to an additional approximately 37 million with type 2 diabetes. Many T2D patients resist starting injectable therapy despite clinical need. An oral daily pill with no food or water restrictions directly addresses that barrier. The filing under the CNPV program means the review timeline could potentially be compressed, though the FDA’s approach to repeat CNPV submissions for the same molecule has not been tested. If the CNPV review mirrors the 50-day timeline from the obesity approval, the diabetes label could arrive before Foundayo’s obesity launch has reached full commercial velocity—creating a second growth catalyst before the first has fully matured.
Our Pro brief includes a detailed breakdown of the Foundayo launch in context—what 3,707 TRx actually means on a normalized basis, why the IQVIA data may undercount LillyDirect and telehealth prescriptions, and what the trajectory needs to look like by Week 12 to hit the revised $1.3B to $1.7B estimates. [Details below.]
Strategic Themes
1. The Volume-Over-Price Thesis Is Being Validated in Real Time
65% volume growth overwhelming 13% price declines is the single most important datapoint in the entire quarter. It proves that Lilly’s strategy of cutting self-pay prices to expand the addressable market is working at the revenue level. As long as demand elasticity exceeds price concession—as long as each dollar of price reduction generates more than a dollar of volume-driven revenue—Lilly can continue to lower barriers to access without sacrificing growth. This dynamic is the foundation of the company’s entire commercial strategy, and Q1 validated it more convincingly than any prior quarter.
2. GLP-1s at Two-Thirds of Revenue Is Both a Strength and a Concentration Risk
$12.8 billion from Mounjaro and Zepbound out of $19.8 billion total means GLP-1s now account for approximately 65% of Lilly’s revenue. That concentration is simultaneously the source of Lilly’s extraordinary growth and its most significant vulnerability. Any disruption to the GLP-1 thesis—a safety signal, a competitor breakthrough, a pricing intervention, a coverage restriction—would have an outsized impact on the company’s financial performance. The six acquisitions announced this year (totaling nearly $20 billion) are explicitly designed to reduce this concentration over time, and the 160% growth in non-metabolic key products shows the diversification is beginning to bear fruit. But for now, Lilly’s story remains a GLP-1 story.
3. Foundayo’s Slow Start Does Not Mean the Launch Is Failing—But It Needs to Accelerate
3,707 prescriptions in Week 2 versus analyst expectations of 8,000 is a miss. But the drug has been commercially available for less than three weeks. Ricks says 20,000-plus patients have started treatment, suggesting that IQVIA data do not capture the full picture. Telehealth channels represent 35% of volume. The drug is a new brand, new molecule, and new mechanism that requires physician education and patient awareness that established brands do not need. RBC says Weeks 8 through 12 are the right window for evaluation. All of that context argues for patience. But the trajectory needs to steepen. Novo’s oral Wegovy hit 18,410 in Week 2. Foundayo hit 3,707. If that gap does not close meaningfully over the next month, the “it’s early” narrative will lose credibility.
4. The Diabetes Filing Could Be Foundayo’s Real Inflection
The obesity launch is important, but the diabetes filing may ultimately matter more for Foundayo’s commercial trajectory. Adding 37 million T2D patients to the addressable market, with the ACHIEVE-4 data package showing cardiovascular safety and a mortality signal, transforms Foundayo from an obesity drug competing with oral Wegovy into a broad metabolic therapy with the most extensive clinical dataset of any oral GLP-1. Filing late Q2 with potential approval before year-end means the diabetes label could arrive before the Foundayo obesity launch has even reached its full commercial run rate—creating a second growth vector before the first has matured.
Frequently Asked Questions
How did Lilly’s Q1 revenue compare to expectations?
$19.8 billion versus consensus of $17.6 billion to $17.8 billion, a beat of more than $2 billion. Revenue grew 56% year-over-year. Non-GAAP EPS was $8.55 versus consensus of $6.66 to $6.79.
How much did Mounjaro and Zepbound generate?
Mounjaro: $8.7 billion (+125%). Zepbound: $4.1 billion (+79%). Combined: $12.8 billion, representing approximately two-thirds of total revenue.
How did Lilly grow revenue while cutting prices?
Volume grew 65%, more than offsetting a 13% decline in realized prices from self-pay price cuts. The demand expansion generated by lower prices produced more revenue growth than the price reductions removed.
How is Foundayo’s launch tracking?
More than 20,000 patients have started the drug according to CEO Ricks. IQVIA data show 3,707 prescriptions in Week 2 (ending April 17), up 167% from 1,390 in the partial first week but below analyst expectations of approximately 8,000. For comparison, Novo’s oral Wegovy hit 18,410 in its second full week. Analysts have revised 2026 Foundayo revenue estimates from $4B to $5B down to approximately $1.3B to $1.7B. RBC says Weeks 8 through 12 are the earliest window to assess true momentum.
Why might IQVIA data undercount Foundayo prescriptions?
Lilly said 12-plus major telehealth firms are offering Foundayo, accounting for about 35% of launch volume. Some prescriptions through LillyDirect and certain telehealth platforms may not report through traditional pharmacy data systems that IQVIA tracks. The 20,000-plus patient figure cited by Ricks suggests broader adoption than the IQVIA numbers alone indicate.
What guidance did Lilly give for 2026?
Revenue: $82 billion to $85 billion (raised from $80 billion to $83 billion). Non-GAAP EPS: $35.50 to $37.00 (raised from $33.50 to $35.00). Both raised by approximately $2 billion at each end, with the midpoints above prior consensus.
When will Lilly file Foundayo for diabetes?
CSO Skovronsky confirmed the type 2 diabetes submission will be completed in late Q2 2026, with regulatory action anticipated before year-end. The filing is supported by ACHIEVE-4 data showing MACE-4 non-inferiority (HR 0.84), 23% lower MACE-3 risk, 57% lower all-cause death (HR 0.43), superior A1C reduction, and 8.8% body weight loss versus insulin glargine.
What is the December 7 Investment Community Meeting?
A major investor event where Lilly will likely lay out its long-term strategy spanning GLP-1s, in vivo CAR-T (Kelonia, Orna), oncology (Ajax, CrossBridge), narcolepsy (Centessa), and gene editing (Profluent). This will be the first comprehensive presentation of how Lilly integrates its six 2026 acquisitions into a unified long-term growth framework.
BioMed Nexus Pro — What Institutional Subscribers Are Reading Today
Lilly Earnings Deep Dive. We analyze why the beat was even bigger than the headline numbers suggest, what 65% volume growth overcoming 13% price declines means for the long-term GLP-1 market thesis, and how the 160% growth in non-metabolic key products validates the diversification strategy that six acquisitions were designed to accelerate.
Foundayo Launch Reality Check. We break down what 3,707 TRx in Week 2 actually means on a normalized basis, compare the launch curve to oral Wegovy’s trajectory at the same point, model what the weekly run rate needs to reach by Week 12 to hit revised estimates of $1.3B to $1.7B, and assess whether the IQVIA data gap (20,000 patients versus 3,707 tracked prescriptions) reflects real demand that traditional data systems are missing.
Lilly vs. Novo: The Scorecard Heading into Novo’s Q1. We compile the competitive metrics across injectable GLP-1 revenue, oral GLP-1 launch velocity, self-pay pricing, dosing convenience, Medicare access, and patient growth projections into a single framework that defines the competitive landscape heading into Novo’s earnings report.
Plus: Diabetes filing timeline assessment, ACHIEVE-4 MACE-3 data analysis, guidance revision implications, December 7 Investment Community Meeting preview, and the updated catalyst calendar through ASCO and H2 2026.
About BioMed Nexus
BioMed Nexus delivers institutional-grade intelligence to biotech and pharma executives, investors, and clinicians. Our daily briefings and deep-dive analyses cut through the noise to deliver the strategic insights that drive better decision-making in the life sciences.
Subscribe to receive daily updates and gain access to BioMed Nexus Pro institutional intelligence briefs.
